Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
about
Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.Chemotherapy-induced cardiotoxicity in children.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity.State of the art review: Chemotherapy-induced cardiotoxicity in children.Genetic determinants of anthracycline cardiotoxicity - ready for the clinic?Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?Investigation of the role of DNA methylation in the expression of ERBB2 in human myocardium.Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity.Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity
P2860
Q38895172-514E30B2-8B2C-413F-A1CC-1E10E20BFC69Q39415815-D7AD6A40-740B-45A4-B05F-C35D23EE30F4Q45073135-50ED84FF-BE32-4DB7-9A04-E9621919246EQ46343364-A7240FAD-BBDD-48FE-9655-6EF7B9398740Q47803922-5212CAFC-2480-41EC-B308-3AE7B3836B2EQ48143732-4A5F637E-94D2-4176-A65C-0F3954AF6B04Q48314857-673FBE8B-5C1F-404F-9502-D5B671AAD051Q48331843-15EC525C-F850-45E9-BEF2-E4C7A39A462CQ49953625-A14811CB-3E26-44FF-A8FC-2AE03A9C32A3Q50875570-604C472E-8C80-42CE-ACF8-CD1248663B54Q51816225-D66E2E50-AA36-4530-9FEC-435E646DECA1Q55208199-30A07BB5-5547-4BF6-B6CA-62D52957209EQ55518023-3024E694-3678-4B2F-AD47-7B9C60EBD16BQ58548679-31BC0436-9961-4F03-BF2B-61D29BF54E63
P2860
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Recommendations for genetic te ...... ycline-induced cardiotoxicity.
@en
type
label
Recommendations for genetic te ...... ycline-induced cardiotoxicity.
@en
prefLabel
Recommendations for genetic te ...... ycline-induced cardiotoxicity.
@en
P2093
P2860
P50
P356
P1476
Recommendations for genetic te ...... ycline-induced cardiotoxicity.
@en
P2093
Anne Smith
CPNDS Clinical Practice Recommendations Group
Colin J D Ross
Daniel Bernstein
Karen A Gelmon
Michael J Rieder
Soomi Hwang
Ursula Amstutz
P2860
P304
P356
10.1111/BCP.13008
P407
P50
P577
2016-05-16T00:00:00Z